The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia
Open accessAbstract
BACKGROUND: In severe acquired aplastic anemia, hematopoietic failure is the result of immune-mediated destruction of bone marrow stem and progenitor cells. Immunosuppressive therapy with antithymocyte globulin (ATG) plus cyclosporine is an effective alternative to stem-cell transplantation and improves blood counts and survival. Although horse ATG is the standard therapy, rabbit ATG is more potent in depleting peripheral-blood lymphocytes and is preferred in other clinical circumstances. METHODS: From December 2005 through July 2010, we performed a randomized trial comparing these two ATG formulations in conventional regimens. Patients were treated at a single facility. The primary outcome was hematologic response at 6 months, as determined by blood counts. The study was designed to enroll 60 patients each for the rabbit-ATG and horse-ATG groups and was powered to detect a difference of 25 percentage points in the response rate. RESULTS: A large, unexpected difference was observed in the rate of hematologic response at 6 months in favor of horse ATG (68%; 95% confidence interval [CI], 56 to 80) as compared with rabbit ATG (37%; 95% CI, 24 to 49; P<0.001). Overall survival at 3 years also differed, with a survival rate of 96% (95% CI, 90 to 100) in the horse-ATG group as compared with 76% (95% CI, 61 to 95) in the rabbit-ATG group (P=0.04) when data were censored at the time of stem-cell transplantation, and 94% (95% CI, 88 to 100) as compared with 70% (95% CI, 56 to 86; P=0.008) in the respective groups when stem-cell-transplantation events were not censored. CONCLUSIONS: In a randomized study, rabbit ATG was inferior to horse ATG as a first treatment for severe aplastic anemia, as indicated by hematologic response and survival. (Funded by the Intramural Research Program of the National Institutes of Health; ClinicalTrials.gov number, NCT00260689.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current concepts in the pathophysiology and treatment of aplastic anemia
Young, N. S., Calado, R. T., & Scheinberg, P. (2006) · Blood · doi:10.1182/blood-2006-03-010777 · Cited by 704
Self-citationFrickhofen, N., Kaltwasser, J. P., Schrezenmeier, H., Raghavachar, A., Vogt, H. G., Herrmann, F., Freund, M., Meusers, P., Salama, A., Heimpel, H., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199105093241901 · Cited by 415
Rosenfeld, S., Follmann, D., Nunez, O., & Young, N. S. (2003) · JAMA · doi:10.1001/jama.289.9.1130 · Cited by 396
Self-citationBrennan, D. C., Flavin, K. S., Lowell, J. A., Howard, T. K., Shenoy, S., Burgess, S., Dolan, S., Kano, J. M., Mahon, M., Schnitzler, M. A., et al. (1999) · Transplantation · doi:10.1097/00007890-199904150-00013 · Cited by 375
Lopez, M., Clarkson, M. R., Albin, M., Sayegh, M. H., & Najafian, N. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050422 · Cited by 367
Locasciulli, A., Oneto, R., Bacigalupo, A., Socie, G., Korthof, E., Bekassy, A., Schrezenmeier, H., Passweg, J., Fuhrer, M., & on the behalf of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (SAA-WP, B. (2007) · Haematologica · doi:10.3324/haematol.10075 · Cited by 330
Rosenfeld, S., Kimball, J., Vining, D., & Young, N. (1995) · Blood · doi:10.1182/blood.v85.11.3058.bloodjournal85113058 · Cited by 319
Self-citationBacigalupo, A. P., Bruno, B., Saracco, P., Bona, E. D., Locasciulli, A., Locatelli, F., Gabbas, A., Dufour, C., Arcese, W., Testi, G., et al. (2000) · Blood · doi:10.1182/blood.v95.6.1931 · Cited by 269
Kojima, S., Hibi, S., Kosaka, Y., Yamamoto, M., Tsuchida, M., Mugishima, H., Sugita, K., Yabe, H., Ohara, A., & Tsukimoto, I. (2000) · Blood · doi:10.1182/blood.v96.6.2049 · Cited by 253
Feng, X., Kajigaya, S., Solomou, E. E., Keyvanfar, K., Xu, X., Raghavachari, N., Munson, P. J., Herndon, T. M., Chen, J., & Young, N. S. (2008) · Blood · doi:10.1182/blood-2008-01-130146 · Cited by 241
Self-citation
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Guidelines for the diagnosis and management of adult aplastic anaemia
Killick, S. B., Bown, N., Cavenagh, J., Dokal, I., Foukaneli, T., Hill, A., Hillmen, P., Ireland, R., Kulasekararaj, A., Mufti, G., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13853 · Cited by 749
Young, N. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1413485 · Cited by 722
Self-citationSomatic Mutations and Clonal Hematopoiesis in Aplastic Anemia
Yoshizato, T., Dumitriu, B., Hosokawa, K., Makishima, H., Yoshida, K., Townsley, D., Sato-Otsubo, A., Sato, Y., Liu, D., Suzuki, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414799 · Cited by 646
“Bone marrow transplantation is curative, and patients may also have a response to immunosuppressive therapy.(3,4) With improved survival, the late development of myelodysplastic syndromes, acute myeloid leukemia (AML), or both has been noted in about 15% of patients and termed “clonal evolution.”
BackgroundSelf-citationEltrombopag Added to Standard Immunosuppression for Aplastic Anemia
Townsley, D. M., Scheinberg, P., Winkler, T., Desmond, R., Dumitriu, B., Rios, O., Weinstein, B., Valdez, J., Lotter, J., Feng, X., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613878 · Cited by 562
Self-citationEltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia
Olnes, M. J., Scheinberg, P., Calvo, K. R., Desmond, R., Tang, Y., Dumitriu, B., Parikh, A. R., Soto, S., Biancotto, A., Feng, X., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200931 · Cited by 539
Self-citationHow I treat acquired aplastic anemia
Scheinberg, P., & Young, N. S. (2012) · Blood · doi:10.1182/blood-2011-12-274019 · Cited by 443
Self-citationHow I treat acquired aplastic anemia
Bacigalupo, A. (2017) · Blood · doi:10.1182/blood-2016-08-693481 · Cited by 421
Desmond, R., Townsley, D. M., Dumitriu, B., Olnes, M. J., Scheinberg, P., Bevans, M., Parikh, A. R., Broder, K., Calvo, K. R., Wu, C. O., et al. (2014) · Blood · doi:10.1182/blood-2013-10-534743 · Cited by 402
Self-citationEltrombopag Added to Immunosuppression in Severe Aplastic Anemia
Peffault de Latour, R., Kulasekararaj, A., Iacobelli, S., Terwel, S. R., Cook, R., Griffin, M., Halkes, C. J. M., Recher, C., Barraco, F., Forcade, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109965 · Cited by 304
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Greenberg, P. L., Stone, R. M., Al-Kali, A., Barta, S. K., Bejar, R., Bennett, J. M., Carraway, H., De Castro, C. M., Deeg, H. J., DeZern, A. E., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0007 · Cited by 297
The European Hematology Association Roadmap for European Hematology Research: a consensus document
Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Dohner, H., de Wit, T. D., Eichinger, S., Fibbe, W., Green, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.136739 · Cited by 81
Samelson-Jones, B. J., Finn, J. D., Favaro, P., Wright, J. F., & Arruda, V. R. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.001 · Cited by 50
Metadata
- Authors
- Scheinberg, P., Nunez, O., Weinstein, B., Scheinberg, P., Biancotto, A., Wu, C. O., & Young, N. S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-08-04
- Volume
- 365
- Issue
- 5
- Pages
- 430-438
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2131799119
- Cited by
- 504
- References
- 22
- FWCI
- 19.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.